{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T12:51:27Z","timestamp":1782910287589,"version":"3.54.5"},"reference-count":190,"publisher":"XMLink","issue":"14","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["jkms.org"],"crossmark-restriction":false},"short-container-title":["J Korean Med Sci"],"DOI":"10.3346\/jkms.2024.39.e134","type":"journal-article","created":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T06:36:16Z","timestamp":1712644576000},"update-policy":"https:\/\/doi.org\/10.3346\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Review of COVID-19 Therapeutics by Mechanism: From Discovery to Approval"],"prefix":"10.3346","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-5282-8894","authenticated-orcid":false,"given":"Hee Sun","family":"Choi","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Ajou University School of Medicine, Suwon, Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7880-5916","authenticated-orcid":false,"given":"A Young","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Ajou University School of Medicine, Suwon, Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9052-186X","authenticated-orcid":false,"given":"Jeffrey B.","family":"Kopp","sequence":"additional","affiliation":[{"name":"Kidney Disease Section, Kidney Diseases, Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5552-0917","authenticated-orcid":false,"given":"Cheryl A.","family":"Winkler","sequence":"additional","affiliation":[{"name":"Basic Research Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, MD, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5929-7932","authenticated-orcid":false,"given":"Sung Kweon","family":"Cho","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Ajou University School of Medicine, Suwon, Korea."},{"name":"Basic Research Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, MD, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"18617","published-online":{"date-parts":[[2024]]},"reference":[{"key":"10.3346\/jkms.2024.39.e134_ref1","unstructured":"Centers for Disease Control and Prevention. Basics of COVID-19. Updated 2021. Accessed March 19, 2023.  https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/your-health\/about-covid-19\/basics-covid-19.html"},{"key":"10.3346\/jkms.2024.39.e134_ref2","unstructured":"World Health Organization. WHO COVID-19 dashboard. Updated 2023. Accessed December 24, 2023.  https:\/\/data.who.int\/dashboards\/covid19\/cases?n=c"},{"key":"10.3346\/jkms.2024.39.e134_ref3","unstructured":"National Institutes of Health. Accelerating COVID-19 therapeutic interventions and vaccines (ACTIV). Updated 2023. Accessed March 19, 2023.  https:\/\/www.nih.gov\/research-training\/medical-research-initiatives\/activ#orgchart"},{"issue":"9","key":"10.3346\/jkms.2024.39.e134_ref4","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1056\/NEJMe2034982","volume":"384","author":"Goletti","year":"2021","journal-title":"N Engl J Med"},{"issue":"8","key":"10.3346\/jkms.2024.39.e134_ref5","doi-asserted-by":"crossref","first-page":"e192","DOI":"10.1016\/S1473-3099(20)30483-7","volume":"20","author":"Marshall","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"10.3346\/jkms.2024.39.e134_ref6","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.7326\/M21-1269","volume":"174","author":"LaVange","year":"2021","journal-title":"Ann Intern Med"},{"key":"10.3346\/jkms.2024.39.e134_ref7","unstructured":"U.S. Food and Drug Administration. Coronavirus (COVID-19) update: FDA authorizes first oral antiviral for treatment of COVID-19. Updated 2021. Accessed March 13, 2023.  https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19"},{"key":"10.3346\/jkms.2024.39.e134_ref8","unstructured":"Pfizer. Paxlovid: EPAR - Product information. Updated 2022. Accessed January 8, 2023.  https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/paxlovid-epar-product-information_en.pdf"},{"key":"10.3346\/jkms.2024.39.e134_ref9","unstructured":"U.S. Food and Drug Administration. Paxlovid LOA 02012023. Updated 2023. Accessed March 13, 2023.  https:\/\/www.fda.gov\/media\/155049\/download"},{"issue":"8","key":"10.3346\/jkms.2024.39.e134_ref10","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.3346\/jkms.2023.38.e59","volume":"38","author":"Lee","year":"2023","journal-title":"J Korean Med Sci"},{"issue":"35","key":"10.3346\/jkms.2024.39.e134_ref11","doi-asserted-by":"crossref","first-page":"e272","DOI":"10.3346\/jkms.2023.38.e272","volume":"38","author":"Kim","year":"2023","journal-title":"J Korean Med Sci"},{"issue":"7","key":"10.3346\/jkms.2024.39.e134_ref12","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1002\/jmv.27730","volume":"94","author":"Masyeni","year":"2022","journal-title":"J Med Virol"},{"key":"10.3346\/jkms.2024.39.e134_ref13","unstructured":"U.S. Food and Drug Administration. Coronavirus (COVID-19) update: FDA authorizes additional oral antiviral for treatment of COVID-19 in certain adults. Updated 2021. Accessed March 16, 2023.  https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-additional-oral-antiviral-treatment-covid-19-certain"},{"key":"10.3346\/jkms.2024.39.e134_ref14","unstructured":"European Medicines Agency. Refusal of the marketing authorisation for Lagevrio (molnupiravir). Updated 2023. Accessed March 16, 2023.  https:\/\/www.ema.europa.eu\/en\/documents\/smop-initial\/questions-answers-refusal-marketing-authorisation-lagevrio-molnupiravir_en.pdf"},{"key":"10.3346\/jkms.2024.39.e134_ref15","unstructured":"Merck Sharp & Dohme LLC. Fact sheet for healthcare providers: emergency use authorization for Lagevrio\u2122 (Molnupiravir) capsules [fact sheet]. Updated 2022. Accessed January 8, 2023.  https:\/\/www.fda.gov\/media\/155054\/download"},{"issue":"1","key":"10.3346\/jkms.2024.39.e134_ref16","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/s41392-021-00835-6","volume":"6","author":"Zhang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"10.3346\/jkms.2024.39.e134_ref17","first-page":"100321","volume":"3","author":"Yu","year":"2022","journal-title":"Innovation (Camb)"},{"key":"10.3346\/jkms.2024.39.e134_ref18","unstructured":"U.S. Food and Drug Administration. FDA approves first treatment for COVID-19. Updated 2020. Accessed March 16, 2023.  https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-covid-19"},{"key":"10.3346\/jkms.2024.39.e134_ref19","unstructured":"Gilead Sciences Ireland UC. Veklury: EPAR - product information. Updated 2022. Accessed January 8, 2023.  https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/veklury-epar-product-information_en.pdf"},{"issue":"48","key":"10.3346\/jkms.2024.39.e134_ref20","doi-asserted-by":"crossref","first-page":"e352","DOI":"10.3346\/jkms.2022.37.e352","volume":"37","author":"Jeon","year":"2022","journal-title":"J Korean Med Sci"},{"issue":"44","key":"10.3346\/jkms.2024.39.e134_ref21","doi-asserted-by":"crossref","first-page":"e346","DOI":"10.3346\/jkms.2023.38.e346","volume":"38","author":"Kang","year":"2023","journal-title":"J Korean Med Sci"},{"issue":"8","key":"10.3346\/jkms.2024.39.e134_ref22","first-page":"CD014962","volume":"8","author":"Ansems","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"19","key":"10.3346\/jkms.2024.39.e134_ref23","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","volume":"383","author":"Beigel","year":"2020","journal-title":"N Engl J Med"},{"key":"10.3346\/jkms.2024.39.e134_ref24","unstructured":"R-Pharm. Artlegia (olokizumab) [package insert]. Updated 2022. Accessed March 18, 2023.  http:\/\/olokizumab.com\/"},{"key":"10.3346\/jkms.2024.39.e134_ref25","unstructured":"Junshi Biosciences. Junshi Biosciences announces approval for marketing of VV116 in China. Updated 2020. Accessed March 17, 2023.  https:\/\/www.junshipharma.com\/en\/%E5%90%9B%E5%AE%9E%E7%94%9F%E7%89%A9%E5%AE%A3%E5%B8%83%E5%8F%A3%E6%9C%8D%E6%8A%97%E6%96%B0%E5%86%A0%E7%97%85%E6%AF%92%E8%8D%AF%E7%89%A9%E6%B0%91%E5%BE%97%E7%BB%B4%EF%BC%88vv116%EF%BC%89%E8%8E%B7\/"},{"issue":"12","key":"10.3346\/jkms.2024.39.e134_ref26","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1038\/s41401-022-00895-6","volume":"43","author":"Qian","year":"2022","journal-title":"Acta Pharmacol Sin"},{"key":"10.3346\/jkms.2024.39.e134_ref27","unstructured":"DCGI approves anti-COVID drug developed by DRDO for emergency use. Updated 2021. Accessed March 16, 2023.  https:\/\/pib.gov.in\/PressReleasePage.aspx?PRID=1717007\/"},{"issue":"10","key":"10.3346\/jkms.2024.39.e134_ref28","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.4103\/jfmpc.jfmpc_1338_21","volume":"10","author":"Sahu","year":"2021","journal-title":"J Family Med Prim Care"},{"key":"10.3346\/jkms.2024.39.e134_ref29","unstructured":"European Medicines Agency. EMA recommends approval for use of Kineret in adults with COVID-19. Updated 2021. Accessed March 16, 2023.  https:\/\/www.ema.europa.eu\/en\/news\/ema-recommends-approval-use-kineret-adults-covid-19\/"},{"key":"10.3346\/jkms.2024.39.e134_ref30","unstructured":"Swedish Orphan Biovitrum AB. KINERET\u00ae (anakinra) [package insert]. Updated 2020. Accessed June 17, 2023.  https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/103950s5189lbl.pdf"},{"key":"10.3346\/jkms.2024.39.e134_ref31","unstructured":"Swedish Orphan Biovitrum AB. Kineret: EPAR - product information. Updated 2022. Accessed January 8, 2023.  https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/kineret-epar-product-information_en.pdf"},{"key":"10.3346\/jkms.2024.39.e134_ref32","unstructured":"U.S. Food and Drug Administration. Kineret LOA 11082022. Updated 2022. Accessed March 16, 2023.  https:\/\/www.fda.gov\/media\/163081\/download"},{"key":"10.3346\/jkms.2024.39.e134_ref33","unstructured":"R-PHARM. Synthesizing and developing molecules. Updated 2023. Accessed March 16, 2023.  https:\/\/www.r-pharm.com\/en\/pipeline?pipeline=olokizumab-eng"},{"key":"10.3346\/jkms.2024.39.e134_ref34","unstructured":"European Medicines Agency. EMA recommends approval for use of RoActemra in adults with severe COVID-19. Updated 2021. Accessed March 16, 2023.  https:\/\/www.ema.europa.eu\/en\/news\/ema-recommends-approval-use-roactemra-adults-severe-covid-19"},{"key":"10.3346\/jkms.2024.39.e134_ref35","unstructured":"Genentech, Inc. ACTEMRA\u00ae (tocilizumab) [package insert]. Updated 2022. Accessed June 17, 2023.  https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/125276s138lbl.pdf"},{"key":"10.3346\/jkms.2024.39.e134_ref36","unstructured":"Roche Pharma AG. RoActemra: EPAR - product information. Updated October 2022. Accessed January 8, 2023.  https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/roactemra-epar-product-information_en.pdf"},{"key":"10.3346\/jkms.2024.39.e134_ref37","unstructured":"U.S. Food and Drug Administration. Genentech Actemra tocilizumab LOA 12212022. Updated 2022. Accessed January 8, 2023.  https:\/\/www.fda.gov\/media\/150319\/download"},{"key":"10.3346\/jkms.2024.39.e134_ref38","unstructured":"Biocad. A drug against COVID-19 complications is registered in Russia. Updated 2020. Accessed March 16, 2023.  https:\/\/biocadglobal.com\/posts\/a-drug-against-covid-19-complications-is-registered-in-russia"},{"issue":"10-12","key":"10.3346\/jkms.2024.39.e134_ref39","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1007\/s00011-021-01507-5","volume":"70","author":"Lomakin","year":"2021","journal-title":"Inflamm Res"},{"key":"10.3346\/jkms.2024.39.e134_ref40","unstructured":"Biocad. A Clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19. Updated 2020. Accessed March 16, 2023.  https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04397562"},{"issue":"6","key":"10.3346\/jkms.2024.39.e134_ref41","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s40259-020-00448-5","volume":"34","author":"Atal","year":"2020","journal-title":"BioDrugs"},{"issue":"9","key":"10.3346\/jkms.2024.39.e134_ref42","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1080\/14712598.2020.1798399","volume":"20","author":"Loganathan","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"10.3346\/jkms.2024.39.e134_ref43","unstructured":"European Medicines Agency. Withdrawal of application to change the marketing authorisation for Olumiant (baricitinib). Updated 2022. Accessed March 16, 2023.  https:\/\/www.ema.europa.eu\/en\/documents\/medicine-qa\/questions-answers-withdrawal-application-change-marketing-authorisation-olumiant-baricitinib_en.pdf"},{"key":"10.3346\/jkms.2024.39.e134_ref44","unstructured":"Eli Lilly and Company. Olumiant (baricitinib) [package insert]. Updated 2022. Accessed June 17, 2023.  https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/207924s007lbl.pdf"},{"key":"10.3346\/jkms.2024.39.e134_ref45","unstructured":"Eli Lilly and Company. Fact sheet for healthcare providers emergency use authorization (EUA) of baricitinib [fact sheet]. Updated 2022. Accessed January 8, 2023.  https:\/\/www.fda.gov\/media\/143823\/download"},{"key":"10.3346\/jkms.2024.39.e134_ref46","unstructured":"U.S. Food and Drug Administration. Baricitinib EUA Letter of Authorization 10272022. Updated 2022. Accessed March 16, 2023.  https:\/\/www.fda.gov\/media\/143822\/download"},{"issue":"49","key":"10.3346\/jkms.2024.39.e134_ref47","doi-asserted-by":"crossref","first-page":"e353","DOI":"10.3346\/jkms.2022.37.e353","volume":"37","author":"Park","year":"2022","journal-title":"J Korean Med Sci"},{"issue":"1","key":"10.3346\/jkms.2024.39.e134_ref48","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1056\/NEJMc2214302","volume":"388","author":"Imai","year":"2023","journal-title":"N Engl J Med"},{"key":"10.3346\/jkms.2024.39.e134_ref49","unstructured":"European Medicines Agency. Evusheld (tixagevimab\/cilgavimab) an overview of Evusheld and why it is authorised in the EU. Updated 2022. Accessed March 24, 2023.  https:\/\/www.ema.europa.eu\/en\/documents\/overview\/evusheld-epar-medicine-overview_en.pdf"},{"key":"10.3346\/jkms.2024.39.e134_ref50","unstructured":"U.S. Food and Drug Administration. FDA announces Evusheld is not currently authorized for emergency use in the U.S. Updated 2023. Accessed March 24, 2023.  https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-announces-evusheld-not-currently-authorized-emergency-use-us"},{"key":"10.3346\/jkms.2024.39.e134_ref51","unstructured":"U.S. Food and Drug Administration. Evusheld Letter of Authorization 01262023. Updated 2023. Accessed March 24, 2023.  https:\/\/www.fda.gov\/media\/154704\/download"},{"key":"10.3346\/jkms.2024.39.e134_ref52","unstructured":"AstraZeneca AB. Evusheld: EPAR - product information. Updated 2022. Accessed January 8, 2023.  https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/evusheld-epar-product-information_en.pdf"},{"key":"10.3346\/jkms.2024.39.e134_ref53","unstructured":"NUVISAN GmbH. Regkirona. EPAR - product information. Updated 2022. Accessed January 8, 2023.  https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/regkirona-epar-product-information_en.pdf"},{"issue":"7898","key":"10.3346\/jkms.2024.39.e134_ref54","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41586-021-04389-z","volume":"602","author":"Planas","year":"2022","journal-title":"Nature"},{"key":"10.3346\/jkms.2024.39.e134_ref55","unstructured":"Roche Pharma AG. Ronapreve: EPAR - product information. Updated 2022. Accessed January 8, 2023.  https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ronapreve-epar-product-information_en.pdf"},{"key":"10.3346\/jkms.2024.39.e134_ref56","unstructured":"U.S. Food and Drug Administration. Coronavirus (COVID-19) update: FDA authorizes additional monoclonal antibody for treatment of COVID-19. Updated 2021. Accessed March 13, 2023.  https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-additional-monoclonal-antibody-treatment-covid-19"},{"key":"10.3346\/jkms.2024.39.e134_ref57","unstructured":"U.S. Food and Drug Administration. FDA updates Sotrovimab emergency use authorization. Updated 2022. Accessed March 13, 2023.  https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-updates-sotrovimab-emergency-use-authorization"},{"key":"10.3346\/jkms.2024.39.e134_ref58","unstructured":"GlaxoSmithKline. Xevudy: EPAR - product information. Updated 2022. Accessed January 8, 2023.  https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xevudy-epar-product-information_en.pdf"},{"issue":"12","key":"10.3346\/jkms.2024.39.e134_ref59","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1007\/s40265-022-01759-3","volume":"82","author":"Hoy","year":"2022","journal-title":"Drugs"},{"issue":"1","key":"10.3346\/jkms.2024.39.e134_ref60","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/s41392-021-00603-6","volume":"6","author":"Bian","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.3346\/jkms.2024.39.e134_ref61","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41392-020-00426-x","volume":"5","author":"Wang","year":"2020","journal-title":"Signal Transduct Target Ther"},{"issue":"7","key":"10.3346\/jkms.2024.39.e134_ref62","doi-asserted-by":"crossref","first-page":"668","DOI":"10.3390\/jpm11070668","volume":"11","author":"Papapanou","year":"2021","journal-title":"J Pers Med"},{"issue":"6532","key":"10.3346\/jkms.2024.39.e134_ref63","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1126\/science.abf4058","volume":"371","author":"White","year":"2021","journal-title":"Science"},{"key":"10.3346\/jkms.2024.39.e134_ref64","unstructured":"Sound Pharmaceuticals. Our product pipeline. Updated 2023. Accessed June 17, 2023.  https:\/\/soundpharma.com\/pipeline\/"},{"issue":"8","key":"10.3346\/jkms.2024.39.e134_ref65","doi-asserted-by":"crossref","first-page":"4865","DOI":"10.1007\/s11033-014-3417-x","volume":"41","author":"Azad","year":"2014","journal-title":"Mol Biol Rep"},{"key":"10.3346\/jkms.2024.39.e134_ref66","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ijsu.2020.10.018","volume":"84","author":"Haritha","year":"2020","journal-title":"Int J Surg"},{"issue":"1","key":"10.3346\/jkms.2024.39.e134_ref67","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1038\/s41467-021-23313-7","volume":"12","author":"Amporndanai","year":"2021","journal-title":"Nat Commun"},{"issue":"9","key":"10.3346\/jkms.2024.39.e134_ref68","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.cmi.2022.04.015","volume":"28","author":"Sendi","year":"2022","journal-title":"Clin Microbiol Infect"},{"issue":"9","key":"10.3346\/jkms.2024.39.e134_ref69","doi-asserted-by":"crossref","first-page":"a2200145","DOI":"10.1056\/EVIDoa2200145","volume":"1","author":"Barnette","year":"2022","journal-title":"NEJM Evid"},{"key":"10.3346\/jkms.2024.39.e134_ref70","unstructured":"Veru Inc. Veru provides FDA update on request for emergency use authorization for sabizabulin for hospitalized COVID-19 patients at high risk for ARDS. Updated 2023. Accessed March 13, 2023.  https:\/\/ir.verupharma.com\/news-events\/press-releases\/detail\/170\/veru-provides-fda-update-on-request-for-emergency-use"},{"issue":"12","key":"10.3346\/jkms.2024.39.e134_ref71","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.3390\/cancers13122896","volume":"13","author":"Mustafa","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.3346\/jkms.2024.39.e134_ref72","unstructured":"AIM ImmunoTech. AIM ImmunoTech announces central IRB approval of phase 2 study protocol evaluating Ampligen\u00ae for the treatment of post-COVID conditions. Updated 2023. Accessed March 13, 2023.  https:\/\/aimimmuno.com\/aim-immunotech-announces-central-irb-approval-of-phase-2-study-protocol-evaluating-ampligen-for-the-treatment-of-post-covid-conditions\/"},{"key":"10.3346\/jkms.2024.39.e134_ref73","unstructured":"Biopharmaceuticals. Pipeline. Updated 2023. Accessed March 18, 2023.  https:\/\/www.zelgen.com\/en\/index.php\/chanpinxian\/"},{"issue":"3","key":"10.3346\/jkms.2024.39.e134_ref74","doi-asserted-by":"crossref","first-page":"161","DOI":"10.5582\/bst.2020.03106","volume":"14","author":"Meng","year":"2020","journal-title":"Biosci Trends"},{"key":"10.3346\/jkms.2024.39.e134_ref75","unstructured":"Novartis Pharmaceuticals. ILARIS\u00ae(canakinumab) [package insert]. Updated 2020. Accessed March 18, 2023.  https:\/\/www.novartis.com\/us-en\/sites\/novartis_us\/files\/ilaris.pdf"},{"key":"10.3346\/jkms.2024.39.e134_ref76","doi-asserted-by":"crossref","first-page":"589654","DOI":"10.3389\/fimmu.2020.589654","volume":"11","author":"Mai","year":"2020","journal-title":"Front Immunol"},{"key":"10.3346\/jkms.2024.39.e134_ref77","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ijid.2020.12.073","volume":"104","author":"Generali","year":"2021","journal-title":"Int J Infect Dis"},{"issue":"3","key":"10.3346\/jkms.2024.39.e134_ref78","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/bjp.2008.270","volume":"155","author":"Zarbock","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.3346\/jkms.2024.39.e134_ref79","unstructured":"Dompe. Research and development pipeline. Updated 2020. Accessed March 19, 2023.  https:\/\/www.dompe.us\/research-and-innovation\/research-and-development-pipeline"},{"issue":"4","key":"10.3346\/jkms.2024.39.e134_ref80","first-page":"1559","volume":"11","author":"Landoni","year":"2022","journal-title":"Infect Dis Ther"},{"key":"10.3346\/jkms.2024.39.e134_ref81","unstructured":"Eli Lilly and Company. TALTZ (ixekizumab) [package insert]. Updated 2022. Accessed March 19, 2023.  https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/125521s024lbl.pdf"},{"issue":"3","key":"10.3346\/jkms.2024.39.e134_ref82","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1111\/bcp.14437","volume":"87","author":"Bulat","year":"2021","journal-title":"Br J Clin Pharmacol"},{"issue":"Suppl 2","key":"10.3346\/jkms.2024.39.e134_ref83","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1186\/ar549","volume":"4","author":"Maini","year":"2002","journal-title":"Arthritis Res"},{"key":"10.3346\/jkms.2024.39.e134_ref84","unstructured":"Janssen Biotech. INFLIXIMAB [package insert]. Updated 2021. Accessed March 19, 2023.  https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/103772s5401lbl.pdf"},{"key":"10.3346\/jkms.2024.39.e134_ref85","unstructured":"Bristol-Myers Squibb Company. ORENCIA (abatacept) [package insert]. Updated 2021. Accessed March 19, 2023.  https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/125118s240lbl.pdf"},{"key":"10.3346\/jkms.2024.39.e134_ref86","doi-asserted-by":"crossref","first-page":"951115","DOI":"10.3389\/fmed.2022.951115","volume":"9","author":"Yang","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.3346\/jkms.2024.39.e134_ref87","unstructured":"Amarin Pharmaceuticals. VASCEPA\u00ae (icosapent ethyl) [package insert]. Updated 2021. Accessed March 19, 2023.  https:\/\/amaringlobal.prod.acquia-sites.com\/sites\/default\/files\/2022-12\/Vascepa-PI.pdf"},{"issue":"9","key":"10.3346\/jkms.2024.39.e134_ref88","doi-asserted-by":"crossref","first-page":"103040","DOI":"10.1016\/j.isci.2021.103040","volume":"24","author":"Kosmopoulos","year":"2021","journal-title":"iScience"},{"key":"10.3346\/jkms.2024.39.e134_ref89","unstructured":"Shaperon. Pipeline - NuSepin\u00ae. Updated 2023. Accessed March 19, 2023.  http:\/\/shaperon.com\/eng\/pipe\/nusepin.php"},{"key":"10.3346\/jkms.2024.39.e134_ref90","unstructured":"Pharming Group. RUCONEST\u00ae [package insert]. Updated 2014. Accessed March 19, 2023.  https:\/\/www.fda.gov\/media\/89212\/download"},{"key":"10.3346\/jkms.2024.39.e134_ref91","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.3389\/fimmu.2020.02072","volume":"11","author":"Urwyler","year":"2020","journal-title":"Front Immunol"},{"key":"10.3346\/jkms.2024.39.e134_ref92","unstructured":"Kyorin Pharmaceutical. KETAS\u00ae [package insert]. Updated 2023. Accessed March 19, 2023.  https:\/\/web.archive.org\/web\/20180830210732\/http:\/www.kyorin-pharm.co.jp\/prodinfo\/medicine\/pdf\/KETAS_Capsules.pdf"},{"issue":"6","key":"10.3346\/jkms.2024.39.e134_ref93","doi-asserted-by":"crossref","first-page":"431","DOI":"10.2217\/nmt-2021-0042","volume":"11","author":"Oskarsson","year":"2021","journal-title":"Neurodegener Dis Manag"},{"issue":"15","key":"10.3346\/jkms.2024.39.e134_ref94","doi-asserted-by":"crossref","first-page":"4964","DOI":"10.3390\/molecules27154964","volume":"27","author":"Crocetti","year":"2022","journal-title":"Molecules"},{"key":"10.3346\/jkms.2024.39.e134_ref95","unstructured":"Capricor Therapeutics, Inc. Product pipeline - CAP-1002. Updated 2023. Accessed March 19, 2023.  https:\/\/capricor.com\/product-pipeline\/cap-1002\/"},{"issue":"4","key":"10.3346\/jkms.2024.39.e134_ref96","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s00395-020-0795-1","volume":"115","author":"Singh","year":"2020","journal-title":"Basic Res Cardiol"},{"key":"10.3346\/jkms.2024.39.e134_ref97","doi-asserted-by":"crossref","first-page":"949264","DOI":"10.3389\/fphar.2022.949264","volume":"13","author":"Humphries","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.3346\/jkms.2024.39.e134_ref98","unstructured":"Galecto. Pipeline. Updated 2023. Accessed March 19, 2023.  https:\/\/galecto.com\/pipeline\/"},{"issue":"12","key":"10.3346\/jkms.2024.39.e134_ref99","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1358\/dot.2012.48.12.1885866","volume":"48","author":"Daly","year":"2012","journal-title":"Drugs Today (Barc)"},{"key":"10.3346\/jkms.2024.39.e134_ref100","unstructured":"Mesoblast. Product candidates overview. Updated 2023. Accessed March 19, 2023.  https:\/\/www.mesoblast.com\/product-candidates\/product-candidates-overview"},{"issue":"5","key":"10.3346\/jkms.2024.39.e134_ref101","doi-asserted-by":"crossref","first-page":"e2020046573","DOI":"10.1542\/peds.2020-046573","volume":"147","author":"Eckard","year":"2021","journal-title":"Pediatrics"},{"key":"10.3346\/jkms.2024.39.e134_ref102","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.3389\/fimmu.2020.02059","volume":"11","author":"Kleen","year":"2020","journal-title":"Front Immunol"},{"key":"10.3346\/jkms.2024.39.e134_ref103","unstructured":"Immodulon. IMM-101 and cancer. Updated 2022. Accessed March 18, 2023.  https:\/\/www.immodulon.com\/immodulon-cancer\/"},{"key":"10.3346\/jkms.2024.39.e134_ref104","unstructured":"Biophytis. Sarconeos (BIO101). Updated 2023. Accessed March 18, 2023.  https:\/\/www.biophytis.com\/en\/our-science\/sarcopenie\/?doing_wp_cron=1676185915.5643670558929443359375\/"},{"issue":"5","key":"10.3346\/jkms.2024.39.e134_ref105","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.drudis.2021.02.010","volume":"26","author":"Latil","year":"2021","journal-title":"Drug Discov Today"},{"key":"10.3346\/jkms.2024.39.e134_ref106","unstructured":"Biophytis. Biophytis announces positive final results of the phase 2-3 COVA study with Sarconeos (BIO101) in severe COVID-19 [Press release]. Updated 2023. Accessed March 18, 2023.  https:\/\/www.biophytis.com\/en\/pdfviewer\/2023-02-02_pr_final_results_cova\/?auto_viewer=true&doing_wp_cron=1679558398.0522260665893554687500#page=%20&zoom=auto&pagemode=none"},{"issue":"8","key":"10.3346\/jkms.2024.39.e134_ref107","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1038\/s41423-021-00719-3","volume":"18","author":"Mu","year":"2021","journal-title":"Cell Mol Immunol"},{"issue":"6","key":"10.3346\/jkms.2024.39.e134_ref108","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/nrc2843","volume":"10","author":"Metcalf","year":"2010","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"10.3346\/jkms.2024.39.e134_ref109","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1189\/jlb.3RU0316-144R","volume":"100","author":"Ushach","year":"2016","journal-title":"J Leukoc Biol"},{"key":"10.3346\/jkms.2024.39.e134_ref110","unstructured":"Partner Therapeutics. Leukine (sargramostim) [package insert]. Updated 2022. Accessed March 18, 2023.  https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/103362s5249lbl.pdf"},{"key":"10.3346\/jkms.2024.39.e134_ref111","doi-asserted-by":"crossref","first-page":"735443","DOI":"10.3389\/fphar.2021.735443","volume":"12","author":"McCormick","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.3346\/jkms.2024.39.e134_ref112","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.3389\/fimmu.2020.01625","volume":"11","author":"Bonaventura","year":"2020","journal-title":"Front Immunol"},{"key":"10.3346\/jkms.2024.39.e134_ref113","unstructured":"Biopharma IM. Product pipeline. Updated 2023. Accessed March 19, 2023.  https:\/\/www.i-mabbiopharma.com\/pipeline\/"},{"issue":"11","key":"10.3346\/jkms.2024.39.e134_ref114","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1016\/j.mayocp.2020.08.038","volume":"95","author":"Temesgen","year":"2020","journal-title":"Mayo Clin Proc"},{"key":"10.3346\/jkms.2024.39.e134_ref115","unstructured":"Humanigen. HGEN Lenzilumab Fact Sheet [Fact sheet]. Updated 2021. Accessed March 18, 2023.  https:\/\/s27.q4cdn.com\/938944131\/files\/governance_doc\/factsheets\/HGEN-Lenzilumab-Fact-Sheet-02-03-21.pdf"},{"key":"10.3346\/jkms.2024.39.e134_ref116","unstructured":"Sanofi Company. LOVENOX (enoxaparin sodium) [package insert]. U.S. Food and Drug Administration website. Updated 2021. Accessed June 17, 2023.  https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/020164s129lbl.pdf"},{"key":"10.3346\/jkms.2024.39.e134_ref117","unstructured":"Pfizer Labs. FRAGMIN\u00ae (dalteparin sodium) [package insert]. Updated 2020. Accessed June 17, 2023.  https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/020287Orig1s076lbl.pdf"},{"key":"10.3346\/jkms.2024.39.e134_ref118","unstructured":"LEO Pharma Inc. Innohep (tinzaparin sodium injection) [package insert]. Updated 2010. Accessed June 17, 2023.  https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/020484s014lbl.pdf"},{"key":"10.3346\/jkms.2024.39.e134_ref119","volume-title":"Heparin","author":"Warnock","year":"2023"},{"issue":"11","key":"10.3346\/jkms.2024.39.e134_ref120","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.3390\/jcm11113099","volume":"11","author":"Mangiafico","year":"2022","journal-title":"J Clin Med"},{"key":"10.3346\/jkms.2024.39.e134_ref121","unstructured":"Xarelto. Updated 2023. Accessed June 17, 2023.  https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xarelto-epar-product-information_en.pdf"},{"key":"10.3346\/jkms.2024.39.e134_ref122","unstructured":"Janssen Pharmaceuticals, Inc. XARELTO\u00ae (rivaroxaban) [package insert]. Updated 2023. Accessed June 17, 2023.  https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/022406s041lbl.pdf"},{"key":"10.3346\/jkms.2024.39.e134_ref123","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ahj.2021.02.001","volume":"235","author":"Capell","year":"2021","journal-title":"Am Heart J"},{"key":"10.3346\/jkms.2024.39.e134_ref124","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ahj.2021.12.010","volume":"246","author":"Hess","year":"2022","journal-title":"Am Heart J"},{"issue":"4","key":"10.3346\/jkms.2024.39.e134_ref125","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1046\/j.1365-2796.2003.01224.x","volume":"254","author":"Lee","year":"2003","journal-title":"J Intern Med"},{"issue":"8","key":"10.3346\/jkms.2024.39.e134_ref126","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1161\/ATVBAHA.122.318748","volume":"43","author":"Hess","year":"2023","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.3346\/jkms.2024.39.e134_ref127","unstructured":"Rigel Pharmaceuticals. TAVALISSE\u2122 (fostamatinib disodium hexahydrate) [package insert]. Updated 2018. Accessed March 19, 2023.  https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/209299lbl.pdf"},{"issue":"6","key":"10.3346\/jkms.2024.39.e134_ref128","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1093\/infdis\/jiaa789","volume":"223","author":"Strich","year":"2021","journal-title":"J Infect Dis"},{"issue":"10","key":"10.3346\/jkms.2024.39.e134_ref129","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/s41577-020-00410-0","volume":"20","author":"Bournazos","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.3346\/jkms.2024.39.e134_ref130","doi-asserted-by":"crossref","first-page":"834988","DOI":"10.3389\/fimmu.2022.834988","volume":"13","author":"Apostolidis","year":"2022","journal-title":"Front Immunol"},{"key":"10.3346\/jkms.2024.39.e134_ref131","unstructured":"Jazz Pharmaceuticals. DEFITELIO (defibrotide sodium) [package insert]. Updated 2016. Accessed March 19, 2023.  https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/208114Orig1s000Lbl.pdf"},{"issue":"2","key":"10.3346\/jkms.2024.39.e134_ref132","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.chest.2022.04.143","volume":"162","author":"Macci\u00f2","year":"2022","journal-title":"Chest"},{"issue":"10","key":"10.3346\/jkms.2024.39.e134_ref133","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s40266-013-0108-6","volume":"30","author":"Berk","year":"2013","journal-title":"Drugs Aging"},{"issue":"1","key":"10.3346\/jkms.2024.39.e134_ref134","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.trci.2019.05.008","volume":"5","author":"Cummings","year":"2019","journal-title":"Alzheimers Dement (N Y)"},{"issue":"10","key":"10.3346\/jkms.2024.39.e134_ref135","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.3390\/v12101092","volume":"12","author":"Al-Horani","year":"2020","journal-title":"Viruses"},{"key":"10.3346\/jkms.2024.39.e134_ref136","unstructured":"Biomed Industries. Pipeline. Updated 2021. Accessed June 17, 2023.  https:\/\/www.biomedind.com\/technology.html"},{"issue":"9","key":"10.3346\/jkms.2024.39.e134_ref137","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/s41581-022-00587-8","volume":"18","author":"Taylor","year":"2022","journal-title":"Nat Rev Nephrol"},{"key":"10.3346\/jkms.2024.39.e134_ref138","doi-asserted-by":"crossref","first-page":"621054","DOI":"10.3389\/fphar.2020.621054","volume":"11","author":"Poloznikov","year":"2021","journal-title":"Front Pharmacol"},{"issue":"Suppl 1","key":"10.3346\/jkms.2024.39.e134_ref139","first-page":"S110","volume":"21","author":"Haase","year":"2017","journal-title":"Hemodial Int"},{"key":"10.3346\/jkms.2024.39.e134_ref140","unstructured":"Genentech. AVASTIN [package insert]. Updated 2022. Accessed March 17, 2023.  https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/125085s340lbl.pdf"},{"key":"10.3346\/jkms.2024.39.e134_ref141","doi-asserted-by":"crossref","first-page":"102017","DOI":"10.1016\/j.ctrv.2020.102017","volume":"86","author":"Garcia","year":"2020","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"10.3346\/jkms.2024.39.e134_ref142","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/s41467-021-21085-8","volume":"12","author":"Pang","year":"2021","journal-title":"Nat Commun"},{"key":"10.3346\/jkms.2024.39.e134_ref143","unstructured":"Akebia Therapeutics I. Research & development. Updated 2022. Accessed March 17, 2023.  https:\/\/akebia.com\/research-and-development\/"},{"key":"10.3346\/jkms.2024.39.e134_ref144","unstructured":"Akebia Therapeutics. Akebia therapeutics announces initial findings from investigator-sponsored clinical study evaluating vadadustat for the prevention and treatment of acute respiratory distress syndrome (ARDS) in subjects with COVID-19 and hypoxemia (VSTAT) [Press release]. Updated 2022. Accessed March 17, 2023.  https:\/\/ir.akebia.com\/news-releases\/news-release-details\/akebia-therapeutics-announces-initial-findings-investigator\/"},{"key":"10.3346\/jkms.2024.39.e134_ref145","unstructured":"Biotest. Development pipeline - Trimodulin (BT-588, IgM Concentrate). Updated 2023. Accessed March 18, 2023.  https:\/\/www.biotest.com\/de\/en\/r_d\/pipeline\/trimodulin.cfm\/"},{"key":"10.3346\/jkms.2024.39.e134_ref146","doi-asserted-by":"crossref","first-page":"700429","DOI":"10.3389\/fimmu.2021.700429","volume":"12","author":"Bohl\u00e4nder","year":"2021","journal-title":"Front Immunol"},{"key":"10.3346\/jkms.2024.39.e134_ref147","unstructured":"Octapharma. Octagam [package insert]. Updated 2022. Accessed March 18, 2023.  https:\/\/www.fda.gov\/media\/157417\/download"},{"key":"10.3346\/jkms.2024.39.e134_ref148","doi-asserted-by":"crossref","first-page":"107732","DOI":"10.1016\/j.intimp.2021.107732","volume":"96","author":"Xiang","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"10.3346\/jkms.2024.39.e134_ref149","unstructured":"RedHill Biopharma. RedHill biopharma reports that opaganib mechanism not impacted by viral spike-protein mutations, including omicron mutations. Updated 2021. Accessed March 18, 2023.  https:\/\/www.redhillbio.com\/news\/news-details\/2021\/RedHill-Biopharma-Reports-that-Opaganib-Mechanism-Not-Impacted-by-Viral-Spike-Protein-Mutations-Including-Omicron-Mutations\/default.aspx"},{"key":"10.3346\/jkms.2024.39.e134_ref150","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.2147\/DDDT.S367612","volume":"16","author":"Smith","year":"2022","journal-title":"Drug Des Devel Ther"},{"key":"10.3346\/jkms.2024.39.e134_ref151","unstructured":"60 Degrees Pharmaceuticals. ARAKODA\u2122 (tafenoquine) [package insert]. Updated 2018. Accessed June 17, 2023.  https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210607lbl.pdf"},{"issue":"3","key":"10.3346\/jkms.2024.39.e134_ref152","doi-asserted-by":"crossref","first-page":"101658","DOI":"10.1016\/j.jbc.2022.101658","volume":"298","author":"Chen","year":"2022","journal-title":"J Biol Chem"},{"key":"10.3346\/jkms.2024.39.e134_ref153","unstructured":"Pharmaceuticals AN. FLUVOXAMINE MALEATE [package insert]. Updated 2021. Accessed March 18, 2023.  https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/021519s018lbl.pdf"},{"key":"10.3346\/jkms.2024.39.e134_ref154","doi-asserted-by":"crossref","first-page":"652688","DOI":"10.3389\/fphar.2021.652688","volume":"12","author":"Sukhatme","year":"2021","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.3346\/jkms.2024.39.e134_ref155","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1186\/1475-2875-11-270","volume":"11","author":"Croft","year":"2012","journal-title":"Malar J"},{"key":"10.3346\/jkms.2024.39.e134_ref156","unstructured":"Shin Poong Pharmaceutical. Pyramax. Updated 2023. Accessed June 17, 2023.  https:\/\/www.ema.europa.eu\/en\/documents\/outside-eu-product-information\/pyramax-product-information_en.pdf"},{"issue":"1","key":"10.3346\/jkms.2024.39.e134_ref157","doi-asserted-by":"crossref","first-page":"14571","DOI":"10.1038\/s41598-021-93361-y","volume":"11","author":"Zhou","year":"2021","journal-title":"Sci Rep"},{"issue":"6","key":"10.3346\/jkms.2024.39.e134_ref158","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1021\/acsinfecdis.2c00091","volume":"8","author":"Puhl","year":"2022","journal-title":"ACS Infect Dis"},{"issue":"1","key":"10.3346\/jkms.2024.39.e134_ref159","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13148-019-0696-z","volume":"11","author":"Tsujikawa","year":"2019","journal-title":"Clin Epigenetics"},{"key":"10.3346\/jkms.2024.39.e134_ref160","unstructured":"RESVERLOGIX. APABETALONE Fact Sheet [Fact sheet]. Updated 2022. Accessed March 18, 2023.  https:\/\/www.resverlogix.com\/upload\/button\/1\/1ad25dfeaa7a\/fact-sheet---jan.-2022.pdf"},{"issue":"4","key":"10.3346\/jkms.2024.39.e134_ref161","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3390\/biomedicines9040437","volume":"9","author":"Gilham","year":"2021","journal-title":"Biomedicines"},{"key":"10.3346\/jkms.2024.39.e134_ref162","unstructured":"NeuroBo Pharmaceuticals, Inc. ANA001. Updated 2023. Accessed March 18, 2023.  https:\/\/www.neurobopharma.com\/ana-001"},{"issue":"13","key":"10.3346\/jkms.2024.39.e134_ref163","doi-asserted-by":"crossref","first-page":"3250","DOI":"10.1111\/bph.15843","volume":"179","author":"Singh","year":"2022","journal-title":"Br J Pharmacol"},{"issue":"12","key":"10.3346\/jkms.2024.39.e134_ref164","doi-asserted-by":"crossref","first-page":"8195","DOI":"10.1007\/s11033-021-06770-7","volume":"48","author":"Al-Kuraishy","year":"2021","journal-title":"Mol Biol Rep"},{"key":"10.3346\/jkms.2024.39.e134_ref165","unstructured":"Kinarus Therapeutics Holding AG. Therapeutic approach. Updated 2023. Accessed March 18, 2023.  https:\/\/www.kinarus.com\/programs-and-pipeline\/therapeutic-approach.htm"},{"issue":"12","key":"10.3346\/jkms.2024.39.e134_ref166","doi-asserted-by":"crossref","first-page":"6830","DOI":"10.3390\/ijms23126830","volume":"23","author":"Setz","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.3346\/jkms.2024.39.e134_ref167","unstructured":"Karyopharm Therapeutics. XPOVIO (selinexor) [package insert]. Updated 2022. Accessed March 18, 2023.  https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/212306s011lbl.pdf"},{"key":"10.3346\/jkms.2024.39.e134_ref168","doi-asserted-by":"crossref","first-page":"884228","DOI":"10.3389\/fphar.2022.884228","volume":"13","author":"Mostafa-Hedeab","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.3346\/jkms.2024.39.e134_ref169","unstructured":"Romark. ALINIA\u00ae (nitazoxanide) [package insert]. Updated 2022. Accessed March 18, 2023.  https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/021497s018,021498s019lbl.pdf"},{"key":"10.3346\/jkms.2024.39.e134_ref170","doi-asserted-by":"crossref","first-page":"173748","DOI":"10.1016\/j.ejphar.2020.173748","volume":"891","author":"Lokhande","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"10.3346\/jkms.2024.39.e134_ref171","unstructured":"SaNOtize. VirX-enovid. Updated 2023. Accessed March 18, 2023.  https:\/\/sanotize.com\/virx-enovid\/"},{"key":"10.3346\/jkms.2024.39.e134_ref172","doi-asserted-by":"crossref","first-page":"100036","DOI":"10.1016\/j.lansea.2022.100036","volume":"3","author":"Tandon","year":"2022","journal-title":"Lancet Reg Health Southeast Asia"},{"issue":"19","key":"10.3346\/jkms.2024.39.e134_ref173","doi-asserted-by":"crossref","first-page":"12803","DOI":"10.3390\/ijerph191912803","volume":"19","author":"Alqahtani","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"10.3346\/jkms.2024.39.e134_ref174","unstructured":"Valeo Pharma. Valeo Pharma receives Hesperco\u2122 natural product license approval from Health Canada. Updated 2020. Accessed March 18, 2023.  https:\/\/www.newswire.ca\/news-releases\/valeo-pharma-receives-hesperco-tm-natural-product-license-approval-from-health-canada-828846612.html"},{"issue":"8","key":"10.3346\/jkms.2024.39.e134_ref175","doi-asserted-by":"crossref","first-page":"742","DOI":"10.3390\/antiox9080742","volume":"9","author":"Bellavite","year":"2020","journal-title":"Antioxidants"},{"key":"10.3346\/jkms.2024.39.e134_ref176","unstructured":"Viatris Specialty LL. LIPITOR\u00ae (atorvastatin calcium) [package insert]. Updated 2022. Accessed January 8, 2023.  https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/020702Orig1s079correctedlbl.pdf"},{"key":"10.3346\/jkms.2024.39.e134_ref177","first-page":"e068407","volume":"376","author":"INSPIRATION-S Investigators","year":"2022","journal-title":"BMJ"},{"issue":"11","key":"10.3346\/jkms.2024.39.e134_ref178","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/s41582-020-0400-0","volume":"16","author":"Dalakas","year":"2020","journal-title":"Nat Rev Neurol"},{"key":"10.3346\/jkms.2024.39.e134_ref179","unstructured":"UCB. Clinical studies index - Zilucoplan (RA101495). Updated 2023. Accessed March 18, 2023.  https:\/\/www.ucb.com\/clinical-studies\/Clinical-studies-index\/Zilucoplan-RA101495"},{"issue":"1","key":"10.3346\/jkms.2024.39.e134_ref180","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/s12931-022-02126-2","volume":"23","author":"De Leeuw","year":"2022","journal-title":"Respir Res"},{"issue":"4","key":"10.3346\/jkms.2024.39.e134_ref181","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/cts.13213","volume":"15","author":"Vlaar","year":"2022","journal-title":"Clin Transl Sci"},{"key":"10.3346\/jkms.2024.39.e134_ref182","unstructured":"InflaRx. Pipeline. Updated 2023. Accessed March 18, 2023.  https:\/\/www.inflarx.de\/Home\/Research---Development\/Pipeline.html"},{"issue":"12","key":"10.3346\/jkms.2024.39.e134_ref183","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S2213-2600(22)00297-1","volume":"10","author":"Vlaar","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.3346\/jkms.2024.39.e134_ref184","unstructured":"Pharmazz. Lyfaquin (Centhaquine citrate) [product information]. Updated 2020. Accessed March 19, 2023.  http:\/\/www.lyfaquin.in\/img\/docs\/Prescribing-Information.pdf"},{"issue":"9","key":"10.3346\/jkms.2024.39.e134_ref185","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s40265-021-01547-5","volume":"81","author":"Gulati","year":"2021","journal-title":"Drugs"},{"issue":"5","key":"10.3346\/jkms.2024.39.e134_ref186","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1056\/NEJMoa2208822","volume":"388","author":"Cao","year":"2023","journal-title":"N Engl J Med"},{"key":"10.3346\/jkms.2024.39.e134_ref187","doi-asserted-by":"crossref","first-page":"899633","DOI":"10.3389\/fphar.2022.899633","volume":"13","author":"Huang","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.3346\/jkms.2024.39.e134_ref188","unstructured":"Biocon, L. Efficacy and safety of itolizumab in COVID-19 complications. Updated 2020. Accessed March 19, 2023.  https:\/\/www.cochranelibrary.com\/central\/doi\/10.1002\/central\/CN-02137238\/full"},{"issue":"6","key":"10.3346\/jkms.2024.39.e134_ref189","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.thromres.2010.09.008","volume":"127","author":"Samama","year":"2011","journal-title":"Thromb Res"},{"issue":"10","key":"10.3346\/jkms.2024.39.e134_ref190","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s40267-018-0551-x","volume":"34","author":"McKeage","year":"2018","journal-title":"Drugs Ther Perspect"}],"container-title":["Journal of Korean Medical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jkms.org\/pdf\/10.3346\/jkms.2024.39.e134","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jkms.org\/DOIx.php?id=10.3346\/jkms.2024.39.e134","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jkms.org\/DOIx.php?id=10.3346\/jkms.2024.39.e134","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T00:02:26Z","timestamp":1713139346000},"score":1,"resource":{"primary":{"URL":"https:\/\/jkms.org\/DOIx.php?id=10.3346\/jkms.2024.39.e134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":190,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.3346\/jkms.2024.39.e134","relation":{},"ISSN":["1011-8934","1598-6357"],"issn-type":[{"value":"1011-8934","type":"print"},{"value":"1598-6357","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"2024-01-11","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-18","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-09","name":"published_online","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"\u00a9 2024 The Korean Academy of Medical Sciences.","name":"copyright","label":"Copyright","group":{"name":"Copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.","name":"license","label":"License","explanation":{"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},"group":{"name":"Copyright_and_licensing","label":"Copyright and Licensing"}}],"article-number":"e134"}}